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Abstract
Background: This case report draws attention to the debated role of prophylactic oophorectomy in women
undergoing definitive surgical resection of colon and rectal cancers. It can be challenging to discern the indications
and appropriate patient population for this procedure based on the current literature. Potential benefits include
treatment and prevention of metastatic disease, preventing development of primary ovarian cancer, and
prolonging survival. Negative effects include an increase in operative time and potential morbidity, development
of osteoporosis, the risk of cardiac events, and decreasing sexual function. Multiple patient factors such as age,
menopausal status, patient preference, presence of hereditary conditions, exposure to radiation, site, and stage
of disease should be considered.
Case presentation: We present a case in which a premenopausal 49-year-old female underwent a prophylactic
bilateral salpingo-oophorectomy concurrently with a low anterior resection following neoadjuvant chemoradiation for
clinical stage III rectal cancer. On pathologic examination, resection margins and all 14 lymph nodes harvested were
negative for malignancy. Interestingly, she was found to have micrometastatic adenocarcinoma in the bilateral ovaries
which had appeared grossly normal at the time of surgery.
Conclusions: After consideration of the current literature, patient preference, and our clinical judgment, our patient
ultimately had a therapeutic effect after undergoing prophylactic bilateral oophorectomy concurrently with a low
anterior resection for rectal cancer. The addition of prophylactic oophorectomy in a select population, specifically
women 50 years of age or younger and/or women who are in the premenopausal state, may carry a survival benefit
in the setting of definitive surgical resection of colon and rectal cancers.
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Background
In this case report, we present a patient who underwent
a prophylactic oophorectomy (PO) during a low anterior
resection for clinical stage III rectal cancer after neoad-
juvant chemotherapy and radiation who was found to
have micrometastatic adenocarcinoma in the bilateral
ovaries. The role of PO in primary colorectal cancers is
controversial. Proposed benefits include decreasing
disease recurrence, preventing development of primary
ovarian cancer, and prolonging survival; however, there
is limited data to support these proposals [1–3]. While
the risk of immediate complications from the procedure
are minimal, patients may experience long-term negative
consequences including decreased sexual function, de-
velopment of osteoporosis, and increased risk of cardiac
events [4]. These negative consequences are largely offset
by the use of exogenous estrogen therapy. The balance of
the risks and benefits are affected by multiple patient
factors including patient preference, age, menopausal* Correspondence: irons-robin@cooperhealth.edu
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status, presence of hereditary conditions, site, and stage of
disease.
Case presentation
Our patient is a 49-year-old, previously healthy, premen-
opausal female who presented to an outside institution’s
emergency department with a chief complaint of new
onset, left lower quadrant pain and several weeks of
constipation. She underwent her first colonoscopic
evaluation which demonstrated a near obstructing mass
at the rectosigmoid junction. She was transferred to our
institution for comprehensive cancer care.
On admission interview, she reported that her ob-
structive symptoms had been progressively escalating,
with her last bowel movement over a week ago. She de-
nied personal history of cancer. Her family history was
significant for a grandmother with gastric cancer in her
late 60s. Pathology identified the mass as a moderately
differentiated, invasive adenocarcinoma. She underwent a
computed tomography (CT) scan of the chest, abdomen,
and pelvis for staging. Imaging revealed wall thickening at
the rectosigmoid junction and luminal narrowing (Fig. 1).
Suspicious perirectal lymph nodes were present, but there
was no evidence of distant metastasis (Fig. 2). Due to
her progressive obstructive symptoms and abdominal
pain, she was taken to the operating room for a
diverting loop ileostomy and a rigid sigmoidoscopy
which demonstrated the distal border of the lesion at
approximately 9 cm from the anal verge.
During her initial admission, she was evaluated by our
hematology/oncology and our radiation oncology de-
partment for outpatient neoadjuvant therapy. She under-
went an MRI of the pelvis to further assist in staging
which displayed a 4.6 cm mass located in the upper rec-
tum that extended into the muscularis propria, classify-
ing it as a T3b lesion. Enlarged superior rectal lymph
nodes suspicious for malignancy were also noted (Fig. 3).
Given her clinical diagnosis of stage III adenocarcinoma
of the rectum, she was deemed a candidate for chemo-
therapy with 5-fluorouracil continuous infusion and con-
current radiation followed by definitive surgical resection.
Ten weeks after completion of preoperative chemora-
diation, she underwent a repeat CT scan (Fig. 4). She
had an appropriate response as evident by decreased
rectal wall thickening and resolution of perirectal lymph
node enlargement to the extent that nodes were no
longer visualized.
She then underwent a laparoscopic low anterior resec-
tion. Our gynecology team was consulted prior to the
procedure for a hysterectomy, as the patient was known
to have a 4 cm posterior leiomyoma. Given her age, fam-
ily history, recent chemotherapy, and pelvic radiation,
the gynecologist felt she would benefit from a bilateral
salpingo-oophorectomy which she had also consented
for. On gross inspection, both ovaries appeared normal.
Pathology revealed moderately differentiated, ulcerated
adenocarcinoma of the rectum with a depth of invasion
Fig. 1 Preoperative CT scan demonstrating a focal area of irregular
wall thickening and associated luminal narrowing at the level of the
rectosigmoid junction
Fig. 2 Preoperative CT scan demonstrating multiple, borderline,
perirectal lymph nodes with the largest measuring 1.0 cm
Fig. 3 Preoperative MRI demonstrating the largest (0.9 cm) of
multiple perirectal lymph nodes
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to 0.1 mm from the peritoneal surface (Fig. 5). Proximal,
distal, and radial resection margins were clear of malig-
nancy and 0 of the 14 nodes harvested contained malig-
nancy. Pericolorectal adipose contained tumor deposits
and there was focal extramural vascular invasion. A
3.7 cm subserosal leiomyoma was present on the poster-
ior aspect of the uterus which was consistent with gross
examination. Of greater interest was the presence of
metastatic rectal adenocarcinoma in the cortex of the
left and right ovaries. Immunohistochemical testing of
the rectal tumor for mismatch repair genes, MSH2,
MLH1, MSH6, and PMS2, associated with Lynch syn-
drome, was not suggestive of the disease.
Discussion
In women undergoing colorectal cancer resection, con-
current PO is not generally recommended or performed,
yet it does need to be considered. These women carry a
risk of developing metastatic disease to the ovaries in
addition to their baseline risk of developing primary
ovarian cancer. PO concurrently with definitive bowel
resection has been proposed, as the ovaries are easily ac-
cessible via laparoscopy or laparotomy and resection car-
ries minimal surgical risks. Current literature provides
some insight into the risks women face with ovarian
preservation, but guidelines for PO in this population
have not been established.
Metastasis disease to the ovaries
The rate of metastasis of colorectal cancer to the ovaries in
an average woman ranges from 1.4 to 4% [1, 5]. This rate
significantly increases when evaluating women prior to
menopause or at age 40 years or less [1, 6, 7]. Mackeigan
et al. reviewed the clinical course of 484 women with colo-
rectal cancer seen at Ferguson-Droste-Ferguson Hospital
over an 8-year period. One hundred thirty-seven under-
went oophorectomy with 133 prophylactically performed
for grossly normal or suspicious involvement [7]. Eight
(6%) of the women were found to have metastatic disease
to the ovaries. Premenopausal status was found to be asso-
ciated with a higher rate of metastatic disease to the ovaries
with 22% of premenopausal women affected.
Walton et al. reviewed 37 women with colorectal can-
cer who were less than 40 years old. Metastasis to the
ovaries was noted in 5 (13.2%) of these women. Recalde
et al. identified 18 females diagnosed with colorectal
cancer at age 35 or younger. Four (22%) developed
metastatic disease to the ovaries [5]. Blamey identified
882 women who underwent resection of a primary colo-
rectal cancer. Thirteen (1.4%) later required oophorec-
tomy for ovarian recurrence [1]. The mean age of those
who developed metastases to the ovaries was 51 years
compared to 59 years in those who did not, which met a
statistical significance. The lower incidence of ovarian
recurrence in this study may be related to imperfections
in long-term patient follow-up; therefore, the true
incidence is not known.
Incidence of primary ovarian cancer
According to the 2010–2012 Surveillance, Epidemiology,
and End Results Program, the average woman in the USA
has a 1.3% chance of developing a primary ovarian cancer
in their lifetime with a 5-year survival rate of 46.2%. Age is
a significant risk factor for the development of primary
ovarian cancer with the median age of diagnosis being
63 years and 88% being diagnosed after the age of 45 [8].
Other contributing factors include but are not limited to
obesity, reproductive history, use of hormone replacement
therapy, and environmental factors [9].
McCredie et al. sought to establish the risk of develop-
ing a new primary cancer among those with a history of
colorectal cancer using 20 years of data from the New
South Wales Central Cancer Registry [3]. Patients with a
Fig. 4 Post neoadjuvant therapy CT scan demonstrating resolution
of perirectal lymph node enlargement
Fig. 5 ×50 H&E stain. A small (up to 2.5 mm) focus of adenocarcinoma
is present in the cortex near the surface of the right ovary
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diagnosis of invasive cancer of the colon or rectum who
had survived beyond 2 months were identified. Patients
who were diagnosed with a second primary within the
first 2 months were omitted as they were thought to
have two synchronous cancers. Compared to the general
female population, women with colon cancer were found
to be 2.8 times more likely to develop a primary ovarian
cancer while those with rectal cancer were only 1.1
times more likely. Hereditary predispositions, hormonal
factors, and dietary factors may contribute to this in-
creased risk [3].
While high-dose radiation is known to increase the
risk of developing ovarian cancer, the effect of the lower
doses of radiation, such as those used in neoadjuvant
therapy for colorectal cancer, is unclear. Recently, SEER
data was utilized to retrospectively review the incidence
of ovarian cancer over a 10-year period in 46,404 pa-
tients with rectal or rectosigmoid cancer [10]. Twenty
(0.15%) of the 13,099 patients who were treated with
beam radiation were diagnosed with ovarian cancer
compared to 91 (0.27%) of the 33,305 patients who did
not receive radiation therapy. Authors found a 44% de-
creased risk of ovarian cancer in the group who received
radiation compared to the non-irradiated group. Pitfalls
of this study include its retrospective design, use of
correlation among variables, lack of information on pa-
tients’ exposure to chemotherapy, radon, and total back-
ground exposures.
Based on these studies, risk factors for the develop-
ment of primary ovarian cancer appear to include a
history of colon cancer. Rectal cancer has not been dem-
onstrated to increase risk of primary ovarian cancer
which may be secondary to a protective effect that might
occur with low-dose radiation.
Ovarian cancer in grossly normal ovaries
While gross abnormalities of the ovary can be appreciated
upon visual inspection and palpation, not all metastatic
ovarian disease are grossly apparent. Burt reviewed 493
cases of colorectal cancer treated at Presbyterian Hospital
in New York over a 14-year period and found 17 cases of
metastatic adenocarcinoma to the ovaries [11]. Four (24%)
had grossly normal ovaries on intraoperative inspection.
In the previously mentioned Mackeigan study, 50% of
women found to have ovarian metastases at the time of
surgery had grossly normal ovaries [7].
Impact on survival
Impact of PO on survival within this population has not
been clearly established due to limited sample sizes.
Survival benefits may be affected by multiple patient char-
acteristics including age, presence of hereditary syn-
dromes, and stage of disease. The Mayo Clinic conducted
a prospective, randomized trial encompassing 149 patients
with Dukes’ stages B or C colorectal cancer [12]. Patients
were randomized to either PO or no oophorectomy. Sur-
vival curves suggested a potential survival benefit between
2 and 3 years post intervention, but this was not found to
be a statistically significant difference and it did not persist
at 5 years post intervention.
A retrospective review at the Mayo Clinic did not
show a statistically significant survival advantage for 75
women who underwent oophorectomy when compared
to the 496 patients in the control group [13]. Of interest,
when patients were placed in age-based subgroups, the 5
women who were less than 50 years of age and had
undergone PO survived more than 5 years. Cutait et al.
examined a group of 335 women who underwent surgi-
cal resection of their colorectal cancer [2]. Two hundred
one patients were selected based on individual surgeon’s
preference and judgment to undergo PO at the time of
their initial definitive bowel resection. Four patients were
found to have ovarian metastasis at the time of surgery.
Disease-free survival, overall survival, and recurrence
were evaluated with greater than 5-year follow-up
achieved in 93% of the study population. There was no
difference found in survival or recurrence when patients
were stratified by menopausal status.
Conclusions
Determining the role of PO among women with resect-
able colorectal cancer remains difficult due to the
limited amount of statistically significant data and the
multiple patient variables at play. While older women
are at a higher risk of developing a primary ovarian can-
cer, Walton, Blamey, and Recalde showed that women of
a younger age were at a higher risk of having metastatic
ovarian disease [6]. Additionally, Mackeigan showed an
association with premenopausal status [7]. Although an
improvement in survival is suggested in the women
under 50 years of age, determining the effects of PO on
survival requires a larger collection of data.
Menopausal status, age, chemotherapy, and radiation
exposure, reproductive goals along with perspective on
hormone replacement therapy should also be taken into
consideration when counseling a patient. While the
oophorectomized state is associated with increased risk
of osteoporosis, coronary artery disease, decreased cog-
nitive, and sexual functions, hormone therapy may help
lessen these risks [4].
Given the not insignificant occurrence of incidentally
found metastatic colorectal cancer to the ovaries in
women undergoing resection, in addition to the risk of
developing a primary ovarian cancer in years following
resection, should prophylactic oophorectomy be offered
to all women at the time of colorectal surgery? But more
relevant may be this question in younger women, either
under 50 years of age or in the premenopausal state,
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particularly those with colon cancer or with rectal
cancer not receiving radiation therapy. These women, as
well as those with strong family histories of other can-
cers, should certainly be strongly encouraged to consider
undergoing concomitant oophorectomy.
Our patient was less than 50 years of age at presenta-
tion and had met her reproductive goals. She was pre-
menopausal and underwent chemotherapy and pelvic
radiation as part of her adjuvant therapy which often re-
sults in loss of ovarian function. The purpose of her sur-
gical resection was to eliminate the risks of developing a
primary or metastatic ovarian cancer, understanding the
immediate and long-term risks of the oophorectomized
state. Fortunately for her, the removal of her grossly nor-
mal appearing ovaries eliminated the only metastatic
source of disease recurrence and should by all means
improve her survival.
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